India Declines Patent Extension Application of Bedaquiline: A Remarkable Step Towards Tuberculosis Elimination

In a pivotal decision, an application to extend the patent on bedaquiline submitted by the pharmaceutical company Johnson & Johnson was denied by the Indian Patent Office, an essential drug for the treatment of tuberculosis. This development marks the conclusion of eight years of drug exclusivit...

Descripción completa

Detalles Bibliográficos
Autor principal: Yadav, Sankalp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692960/
https://www.ncbi.nlm.nih.gov/pubmed/38046693
http://dx.doi.org/10.7759/cureus.48146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692960/
https://www.ncbi.nlm.nih.gov/pubmed/38046693
http://dx.doi.org/10.7759/cureus.48146

Ejemplares similares